Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting

Phase 2

Oxaliplatin, Liposomal Irinotecan, TrastuzumabOxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Sponsor:

University of Wisconsin, Madison

Code:

NCT04150640

Conditions

Esophageal Adenocarcinoma

Gastric Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nal-IRI

Oxaliplatin

5-FU

Trastuzumab

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-05. This information was provided to ClinicalTrials.gov by University of Wisconsin, Madison on 2025-07-23.